euro-biopharma-ethnopharmacology-2017-keynote

4 / 13

Volume 6, Issue 4 (Suppl) Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
Page 14
&
6th International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4th EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Next generation of smart stimuli-sensitive siRNA/drug nanopreparations for cancer
Tumor therapy, especially in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA down-
regulating the production of proteins, which are involved in cancer cell resistance, such as Pgp or survivin. Even better
response could be achieved is such siRNA could be delivered to tumors together with chemotherapeutic agent. This task is
complicated by low stability of siRNA in biological surrounding. Thus, the delivery system should simultaneously protect
siRNA from degradation. We have developed several types of lipid-core polymeric micelles based on PEG-phospholipid or
PEI-phospholipid conjugates, which are biologically inert, demonstrate prolonged circulation in the blood and can firmly
bind non-modified or reversibly-modified siRNA. Additionally, these nanopreparations can be loaded into their lipidic core
with poorly water soluble chemotherapeutic agents, such as paclitaxel or camptothecin. In experiments with cancer cell
monolayers, cancer cell 3D spheroids, and in animals with implanted tumors, it was shown that such co-loaded preparations
can significantly down-regulate target proteins in cancer cells, enhance drug activity, and reverse multidrug resistance. In order
to specifically unload such nanopreparations inside tumors, we made them sensitive to local tumor-specific stimuli, such as
lowered pH, hypoxia, or overexpressed certain enzymes, such as matrix metalloproteases. Using pH-, hypoxia-, or MMP2-
sensitive bonds between different components of nanopreparations co-loaded with siRNA and drugs, we were able to make
the systems specifically delivering biologically active agents in tumors, which resulted in significantly improved therapeutic
response.
Biography
Vladimir P Torchilin, PhD, DSc is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomed-
icine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers,
biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12
books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery
Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more
than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number
2 among top world scientists in Pharmacology for the period of 2000-2010.
Vladimir P Torchilin
Northeastern University, USA
Vladimir P Torchilin, Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-024